OralParenteralTherapeutic flag Cosmetic cross-reference

Magnesium Sulfate Anhydrous

CAS 7487-88-9

Magnesium Sulfate Anhydrous (CAS 7487-88-9) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 2,676 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
2,676
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Magnesium Sulfate Anhydrous
CAS Number
7487-88-9
UNII
ML30MJ2U7I
InChIKey
CSNNHWWHGAXBCP-UHFFFAOYSA-L
ChEMBL ID
CHEMBL2021423
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
oralparenteraltherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL2021423 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Premature baby 547 655.363 10036590
Macular degeneration 274 341.822 10025409
Premature delivery 276 329.748 10036595
Normal labour 67 255.655 10029767
Contraindicated product administered 23 220.66 10078504
Low birth weight baby 184 214.708 10067508
Hypermagnesaemia 75 211.769 10020669
Completed suicide 17 207.833 10010144
Synovitis 11 199.545 10042868
Systemic lupus erythematosus 21 191.353 10042945
Delivery 68 190.994 10067647
Hand deformity 4 184.601 10061194
Treatment failure 47 169.715 10066901
Foetal exposure during pregnancy 391 167.742 10071404
Glossodynia 25 148.277 10018388
Exposure during pregnancy 494 148.257 10073513
Product use issue 88 143.034 10076309
Drug intolerance 141 141.718 10061822
Drug abuse 15 136.999 10013654
Cytokine release syndrome 182 125.452 10052015
Toxicity to various agents 209 123.769 10070863
Arthropathy 86 119.418 10003285
Rheumatoid arthritis 107 117.385 10039073
Pericarditis 22 109.304 10034484
Paraesthesia oral 130 100.229 10057372
Joint swelling 192 99.727 10023232
Wound 49 96.875 10052428
Off label use 910 95.243 10053762
Maternal exposure during pregnancy 527 94.948 10071408
Intentional product use issue 77 88.905 10076308
Duodenal ulcer perforation 6 88.257 10013849
Apgar score low 48 86.507 10002944
Therapeutic product effect decreased 89 85.343 10082201
Pulmonary oedema 279 85.246 10037423
PCO2 increased 42 82.898 10034183
Chronic sinusitis 97 82.501 10009137
Unevaluable event 241 81.524 10062355
Postpartum haemorrhage 39 74.517 10036417
Diarrhoea 1705 73.601 10012735
Procedural pain 118 73.201 10064882
Lower respiratory tract infection 54 71.779 10024968
Folliculitis 6 70.864 10016936
Mitochondrial DNA mutation 24 70.46 10052641
Blood pH decreased 52 69.654 10005706
Alopecia 214 69.248 10001760
Discomfort 76 67.063 10013082
Muscle injury 4 66.816 10028314
Arthralgia 555 65.653 10003239
Hepatic enzyme increased 120 63.443 10060795
Intentional overdose 30 61.232 10022523

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
MAGNESIUM SULFATE ANHYDROUS 1311625 SU MTHSPL
Magnesium Sulfate Anhydrous 1311625 SU MTHSPL
magnesium sulfate anhydrous 1311625 PIN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Magnesium Sulfate Anhydrous used for in pharmaceutical contexts?

Magnesium Sulfate Anhydrous (CAS 7487-88-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Magnesium Sulfate Anhydrous?

Magnesium Sulfate Anhydrous has 2,676 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Premature baby, Macular degeneration, Premature delivery, Normal labour, Contraindicated product administered. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Magnesium Sulfate Anhydrous also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Magnesium Sulfate with EU status "permitted".

What clinical phase is Magnesium Sulfate Anhydrous in?

Magnesium Sulfate Anhydrous is rendered with ChEMBL max phase 4 (approved).